Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501207 | 0.88 | CYP19A1 (0.45) | CYP19A1PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL29501215 | 0.83 | CYP19A1 (0.45) | CYP19A1PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL16113024 | 0.83 | CYP19A1 (0.45) | CYP19A1PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL29501245 | 0.81 | CYP19A1 (0.58) | CYP19A1STS | |
| SCHEMBL16114228 | 0.81 | CYP19A1 (0.58) | CYP19A1STS | |
| SCHEMBL16046743 | 0.80 | PIK3CA (0.42) | CYP19A1PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL16114259 | 0.80 | HDAC1 (0.37) | PIK3CA | |
| SCHEMBL20356874 | 0.79 | GRIN1 (0.42) | CYP19A1STS | |
| SCHEMBL16044951 | 0.79 | CYP19A1 (0.45) | CYP19A1PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL16044327 | 0.79 | CYP19A1 (0.43) | CYP19A1PIK3CAPIK3CDPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CYP19A1 2066/4885PIK3CA 222/4885PIK3CD 229/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CYP19A1 2066/4885PIK3CA 222/4885PIK3CD 229/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | CYP19A1 2107/4885PIK3CA 215/4885PIK3CD 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.